Moderna (MRNA) to acquire OriCiro Genomics K.K for $85 million
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Moderna to Acquire OriCiro Genomics
January 4, 2023 7:01 AM ESTOriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines
Acquisition will bolster Moderna's suite of platform technologies
CAMBRIDGE, MA and TOKYO, JAPAN / ACCESSWIRE / January 4, 2023 / Moderna, Inc. (NASDAQ: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and OriCiro Genomics K.K., a pioneer in cell-free DNA synthesis and amplification technologies, today announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million.
"With this... More



